Cary Street Partners’s AstraZeneca AZN Stock Holding History

Cary Street Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.48M	Buy	13,070 +2,674	+26%	+$503K	0.05%	323
2026 Q1	$2.05M	Buy	10,396 +2,213	+27%	+$427K	0.05%	324
2025 Q4	$1.5M	Buy	8,183 +5,378	+192%	+$943K	0.04%	365
2025 Q3	$430K	Sell	2,805 -220	-7%	-$33.3K	0.01%	607
2025 Q2	$423K	Sell	3,025 -128	-4%	-$17.9K	0.01%	596
2025 Q1	$463K	Sell	3,153 -206	-6%	-$29.8K	0.01%	554
2024 Q4	$440K	Buy	+3,359	New	+$470K	0.01%	532

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Cary Street Partners's AZN Position: Q2 2026 in Review

Cary Street Partners increased its AstraZeneca (AZN) stake by 26% in Q2 2026, buying an estimated $503K and bringing the position to 13,070 shares worth $2.48M. The position accounts for 0.05% of the portfolio, ranked #323.

Cary Street Partners first reported a position in AZN in Q4 2024 and has held it in 7 quarters since. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Cary Street Partners held 13,070 shares of AstraZeneca worth $2.48M as of Q2 2026.
Cary Street Partners bought 2,674 AstraZeneca shares in Q2 2026, an estimated $503K.
AstraZeneca made up 0.05% of Cary Street Partners's portfolio in Q2 2026, its #323 holding.
Cary Street Partners first reported a position in AstraZeneca in Q4 2024 and has held it in 7 quarters since.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Cary Street Partners's 13F filing for Q2 2026, filed 17 Jul 2026.